Michigan MD Faces DEA Ban for Sketchy Prescribing and Patient Coaching
Published Date: 5/7/2025
Notice
Summary
Dr. Mohan Kaza from Michigan had his DEA license suspended and is now losing it for giving out strong prescription drugs without proper exams or checks. He also coached undercover agents to lie and charged extra fees for higher doses. This decision protects public safety by stopping unsafe prescribing practices immediately.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Physician
DEA Certificate of Registration No. FK8011063 issued to Mohan Kaza, M.D., is revoked, removing his DEA registration and associated authority to prescribe or dispense controlled substances under that registration. The revocation is ordered by the DEA and takes effect June 6, 2025.
Pending Michigan Registration Applications Denied
DEA denied any pending applications of Mohan Kaza, M.D., to renew or modify his registration and denied any other pending applications for additional registration in Michigan. That denial is part of the same Order effective June 6, 2025.
Order Stops Unsafe Prescribing Practices
The DEA found that between January 17, 2024 and April 17, 2024 the physician issued seven controlled-substance prescriptions to two undercover individuals without proper assessments, coached them to provide false medical histories, dispensed at least one tablet without a prescription, and charged higher cash fees for higher dosages. The Order revokes the registration to protect public safety and stop those unsafe prescribing practices immediately.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
Previous / Next Documents
Previous: 2025-07935 — Edmund Ayoub Jr., M.D.; Decision and Order
Dr. Edmund Ayoub Jr. from California lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. Despite multiple attempts, he didn’t respond or ask for a hearing, so the DEA officially revoked his registration. This means he can’t prescribe or manage controlled drugs anymore, effective immediately, impacting his medical practice and any related income.
Next: 2025-07939 — Change in Control: Mexico Pacific Limited LLC
Mexico Pacific Limited LLC is changing who owns the company’s upstream operations. The Department of Energy got the official notice in March 2025, so this change is now on the record. This update affects anyone tracking energy ownership and could impact future natural gas activities.